1. Home
  2. CEVA vs GOSS Comparison

CEVA vs GOSS Comparison

Compare CEVA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEVA Inc.

CEVA

CEVA Inc.

HOLD

Current Price

$19.69

Market Cap

573.9M

Sector

Technology

ML Signal

HOLD

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.11

Market Cap

615.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CEVA
GOSS
Founded
1999
2015
Country
US
US
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
573.9M
615.7M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
CEVA
GOSS
Price
$19.69
$2.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$33.25
$8.83
AVG Volume (30 Days)
339.9K
5.3M
Earning Date
05-19-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
27.45
78.81
EPS
N/A
N/A
Revenue
$87,507,000.00
$114,701,000.00
Revenue This Year
$14.97
N/A
Revenue Next Year
$12.74
$6.41
P/E Ratio
N/A
N/A
Revenue Growth
20.45
N/A
52 Week Low
$18.23
$0.76
52 Week High
$36.95
$3.87

Technical Indicators

Market Signals
Indicator
CEVA
GOSS
Relative Strength Index (RSI) 35.77 34.84
Support Level $19.30 $2.24
Resistance Level $24.00 $2.50
Average True Range (ATR) 1.25 0.21
MACD -0.23 -0.01
Stochastic Oscillator 8.21 1.53

Price Performance

Historical Comparison
CEVA
GOSS

About CEVA CEVA Inc.

CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: